Dihydrochalcone

Dihydrochalcone

SCHEMBL29359372

O=C(CCc1ccccc1)c1ccccc1O

nearest known ligand 0.80

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.80
MAPT P10636 2/20 0.59
GAA P10253 1/20 0.59
SLC5A1 P13866 1/20 0.59
SLC5A2 P31639 1/20 0.59
CYP1A1 P04798 1/20 0.57
CYP1B1 Q16678 1/20 0.57
KEAP1 Q14145 1/20 0.55
ALDH1A1 P00352 3/20 0.54
HPGD P15428 2/20 0.54
TSHR P16473 2/20 0.54
NPC1 O15118 2/20 0.54
HTT P42858 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
HSD17B10 Q99714 1/20 0.54
NLRP1 Q9C000 1/20 0.54
KDM4E B2RXH2 1/20 0.52
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dihydrochalcone SCHEMBL2827303 1.00 CYP19A1 (0.80) CYP19A1MAPTGAASLC5A1SLC5A2
Dihydrochalcone SCHEMBL7540273 0.98 CYP19A1 (0.77) CYP19A1MAPTGAASLC5A1SLC5A2
SCHEMBL1841587 0.89 CYP19A1 (1.00) CYP19A1MAPTGAASLC5A1SLC5A2
SCHEMBL5793080 0.89 CYP19A1 (0.65) CYP19A1MAPTALDH1A1HPGDTSHR
SCHEMBL30358375 0.86 CYP19A1 (0.71) CYP19A1MAPTGAASLC5A1SLC5A2
SCHEMBL11880560 0.86 ACHE (0.62) CYP19A1MAPTGAASLC5A1SLC5A2
SCHEMBL1733117 0.86 CYP19A1 (0.71) CYP19A1MAPTGAASLC5A1SLC5A2
SCHEMBL10988386 0.86 CYP19A1 (0.76) CYP19A1MAPTGAASLC5A1SLC5A2
SCHEMBL3861193 0.86 CYP19A1 (0.61) CYP19A1MAPTGAASLC5A1SLC5A2
Hydrochloric Acid SCHEMBL3785617 0.84 CYP19A1 (0.69) CYP19A1MAPTGAASLC5A1SLC5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 395 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4655410-A2 O-METHYLATION OF PHENOLIC SUBSTANCES VIA FUNGAL O-METHYLTRANSFERASE Symrise AG (DE) 2025-12-03 EP claimed
WO-2025122010-A1 A METHOD FOR PURIFYING A MODIFIED GELATIN SENTRYX B.V. (NL) 2025-06-12 WO claimed
EP-3689324-B1 NEW COOLING AGENTS AND PREPARATIONS COMPRISING THEM SYMRISE AG (DE) 2024-11-20 EP claimed
EP-4418876-A1 DIHYDROCHALCONE DERIVATIVES Symrise AG (DE) 2024-08-28 EP claimed
WO-2024156359-A1 O-METHYLATION OF PHENOLIC SUBSTANCES VIA FUNGAL O-METHYLTRANSFERASE SYMRISE AG (DE) 2024-08-02 WO claimed
WO-2024156879-A2 O-METHYLATION OF PHENOLIC SUBSTANCES VIA FUNGAL O-METHYLTRANSFERASE SYMRISE AG (DE) 2024-08-02 WO claimed
US-20240245826-A1 BIO-ADHESIVE SENTRYX B.V. (NL) 2024-07-25 US claimed
EP-3422873-B1 LONG-LASTING SWEETENER FORMULATIONS WRIGLEY W M JUN CO (US) 2024-01-31 EP claimed
US-20230364172-A1 MODULATION OF SOLUBILITY, PALATABILITY, ABSORPTION, AND BIOAVAILABILITY OF MITRAGYNA SPECIOSA-DERIVED COMPOUNDS FOR ORAL AND BUCCAL DELIVERY Syncotrance, LLC 2023-11-16 US claimed
US-20230277445-A1 ADHESIVE DRUG CARRIER UMC UTRECHT HOLDING B.V. (NL) 2023-09-07 US claimed
WO-2023066890-A1 DIHYDROCHALCONE DERIVATIVES SYMRISE AG (DE) 2023-04-27 WO claimed
CN-115916156-A Improved adhesive drug carrier UMC乌德勒支控股有限公司 2023-04-04 CN claimed
WO-2023002017-A1 BIO-ADHESIVE SENTRYX B.V. (NL) 2023-01-26 WO claimed
US-20220298226-A1 METHACRYLATED COLLAGEN JELLAGEN LTD (GB) 2022-09-22 US claimed
CN-114813900-A Method for detecting active II type ribosome inactivating protein 中国人民解放军军事科学院军事医学研究院 2022-07-29 CN claimed
EP-3442354-B1 FORMULATION AND PRODUCTION OF SPINACH EXTRACT WITH BETA ECDYSON DR GOETZ GMBH (DE) 2026-05-20 EP disclosed
CN-120130286-B Method for promoting growth of lithocarpus littoralis leaves, synthesis of dihydrochalcone and reduction of heavy metal content 广东省林业科学研究院 2026-05-15 CN disclosed
US-20220031602-A1 SKIN PERFECTING COSMETIC COMPOSITIONS AND METHODS OF USE L'OREAL (FR) 2022-02-03 US disclosed
CN-114007617-A Unit dosage form for transmucosal administration of pharmaceutically active ingredients 葡瑞慕生物技术有限公司 2022-02-01 CN disclosed
US-20220023302-A1 PDE9 INHIBITORS FOR TREATING SICKLE CELL DISEASE CARDURION PHARMACEUTICALS, INC. 2022-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220023302-A1 PDE9 INHIBITORS FOR TREATING SICKLE CELL DISEASE PDE9A, PDE2A, PDE3A CYP19A1 3943/4885MAPT 4311/4885GAA 101/4885
US-20220031602-A1 SKIN PERFECTING COSMETIC COMPOSITIONS AND METHODS OF USE CUTA, DSG1, SMURF1 CYP19A1 386/4885MAPT 1248/4885GAA 3898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.